The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer
|
|---|---|
| Published in |
Frontiers in Pharmacology, July 2021
|
| DOI | 10.3389/fphar.2021.573852 |
| Pubmed ID | |
| Authors |
Xuezhi Hao, Aizong Shen, Bin Wu |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 2 | 14% |
| Professor > Associate Professor | 1 | 7% |
| Student > Ph. D. Student | 1 | 7% |
| Student > Bachelor | 1 | 7% |
| Other | 1 | 7% |
| Other | 0 | 0% |
| Unknown | 8 | 57% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 7% |
| Business, Management and Accounting | 1 | 7% |
| Biochemistry, Genetics and Molecular Biology | 1 | 7% |
| Unknown | 8 | 57% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 July 2021.
All research outputs
#18,807,229
of 23,308,124 outputs
Outputs from Frontiers in Pharmacology
#8,594
of 16,753 outputs
Outputs of similar age
#316,688
of 439,888 outputs
Outputs of similar age from Frontiers in Pharmacology
#410
of 904 outputs
Altmetric has tracked 23,308,124 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,753 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 439,888 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 904 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.